Article Sidebar
Main Article Content
Abstract
Background: Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in acutely ill medical patients. Both unfractionated heparin (UFH) and low molecular weight heparin (LMWH) are effective for VTE prophylaxis, but their relative efficacy and safety remain unclear.
Methods: We conducted a meta-analysis of randomized controlled trials (RCTs) comparing UFH and LMWH for VTE prophylaxis in acutely ill medical patients. We searched MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials from 2013 to 2024. The primary outcome was the incidence of VTE. Secondary outcomes included major bleeding and mortality.
Results: Seven RCTs with a total of 5,412 patients were included. LMWH was associated with a significantly lower risk of VTE compared to UFH (relative risk [RR] 0.68; 95% confidence interval [CI] 0.52-0.88; p = 0.004). There was no significant difference in major bleeding (RR 0.91; 95% CI 0.65-1.27; p = 0.58) or mortality (RR 0.93; 95% CI 0.78-1.11; p = 0.43) between the two groups.
Conclusion: LMWH is more effective than UFH for VTE prophylaxis in acutely ill medical patients without increasing the risk of major bleeding or mortality. LMWH should be considered the preferred agent for VTE prophylaxis in this population.
Keywords
Article Details
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
